Pembrolizumab versus ipilimumab for advanced melanoma: 10-year follow-up of the phase III KEYNOTE-006 study

Bibliographic Details
Title:	Pembrolizumab versus ipilimumab for advanced melanoma: 10-year follow-up of the phase III KEYNOTE-006 study
Authors:	Long, G.V. ^{1, 2, 3, 4, ∗}, Carlino, M.S. ^{1, 2, 5}, McNeil, C. ⁶, Ribas, A. ⁷, Gaudy-Marqueste, C. ⁸, Schachter, J. ⁹, Nyakas, M. ¹⁰, Kee, D. ¹¹, Petrella, T.M. ¹², Blaustein, A. ¹³, Lotem, M. ¹⁴, Arance, A.M. ¹⁵, Daud, A.I. ¹⁶, Hamid, O. ¹⁷, Larkin, J. ¹⁸, Yao, L. ¹⁹, Singh, R. ¹⁹, Lal, R. ¹⁹, Robert, C. ^{20, ∗}
Source:	In Annals of Oncology December 2024 35(12):1191-1199
Database:	ScienceDirect